Core Insights - The globalization process of domestic medical aesthetic devices is accelerating, with Peninsula Medical's ZenTite™ being installed at the Wellman Center for Photomedicine in Boston, a significant achievement for the company [1][4] - ZenTite™ is a fifth-generation gold microneedle developed by Peninsula Medical, designed for precise treatment of facial areas, addressing pain issues associated with traditional microneedles and meeting personalized treatment needs [1][3] - Peninsula Medical has obtained FDA 510(k) registration for ZenTite™, marking it as the first RF microneedling device from China to receive this certification, facilitating entry into the North American market [1][2] Company Developments - Peninsula Medical plans to continue registering other devices for overseas markets, having previously focused on home-use products, and is now expanding into larger equipment [2] - The entry of ZenTite™ into multiple medical institutions in North America signifies a breakthrough for domestic energy-based medical aesthetic devices [4] Market Context - The North American energy-based medical aesthetic device market is projected to dominate globally, accounting for nearly 40% of revenue share in 2023 [2] - The global energy-based medical aesthetic device market is expected to grow from $5.6 billion in 2025 to $24.9 billion by 2034, with a compound annual growth rate (CAGR) of 17.9% [3]